Join CBSET at the RESI Conference, September 25 at the Westin Copley Place, Boston, MA, followed by two days of virtual partnering on September 26-27.
The Redefining Early Stage Investments (RESI) conference series connects start-ups and early-stage investors and strategic channel partners. RESI maximizes fundraising companies’ efforts to find partners who are a fit for their technology and stage of development. RESI is uniquely cross-border and cross-domain, connecting start-ups with 10 categories of global investors across the silos of drugs, devices, diagnostics and digital health (4 Ds). RESI caters to both the earliest stage start-ups, those seeking grants, seed and angel capital, and the early-stage firms who seek series A and B funding. RESI is a unique and powerful tool for sourcing assets and advancing innovation across early-stage life science and healthcare.
CBSET Director of Business Development, Michael Naimark, will be at the meeting.
Please contact us to meet up at the RESI Conference.
Related CBSET research:
"Morphometric analysis of the human common hepatic artery (CHA) reveals a rich and accessible target for sympathetic liver denervation." Abraham Rami Tzafriri PhD, Fernando Garcia-Polite PhD, John Keating DVM DACVP, Raffaele Melidone DVM DACVP, Jennifer Knutson BS, Peter Markham MS, Elazer R. Edelman MD PhD, Felix Mahfoud MD. Scientific Reports, 10.1038/s41598-022-05475-6.
"Arterial microanatomy determines the success of energy-based renal denervation in controlling hypertension." Tzafriri AR, Keating JH, Markham PM, Spognardi AM, L Stanley JR, Wong G, Zani BG, Highsmith D, O'Fallon P, Fuimaono K, Mahfoud F, Edelman ER. Sci Transl Med. 2015 Apr 29;7(285):285ra65. doi: 10.1126/scitranslmed.aaa3236.
"Defining drug and target protein distributions after stent-based drug release: Durable versus deployable coatings." by Tzafriri AR, Garcia-Polite F, Li X, Keating J, Balaguer JM, Zani B, Bailey L, Markham P, Kiorpes TC, Carlyle W, Edelman ER. Journal of Controlled Release, March 28, 2018, Volume 274, Pages 102-108.
"Intracochlear Drug Delivery Systems: A Novel Approach Whose Time Has Come." Peppi M, Marie A, Belline C, Borenstein JT. Expert Opinion on Drug Delivery, Volume 15, Issue 4, March 9, 2018, Pages 319-324.
"A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma." Indolfi L, Ligorio M, Ting DT, Xega K, Tzafriri AR, Bersani F, Aceto N, Thapar V, Fuchs BC, Deshpande V, Baker AB, Ferrone CR, Haber DA, Langer R, Clark JW, Edelman ER. Biomaterials, Volume 93, July 2016, Pages 71-82.
"Percutaneous Hepatic Perfusion With Filtered Melphalan for Localized Treatment of Metastatic Hepatic Disease: A Risk Assessment." Pauline E McEwan, Lynn Bailey, David Trost, Christopher Scull, John H Keating, Misty Williams, Robert J Guttendorf. Int J Toxicol. Nov/Dec 2018;37(6):434-447. doi: 10.1177/1091581818811306.
"Pharmacokinetics and safety of paclitaxel delivery into porcine airway walls by a new endobronchial drug delivery catheter." Tsukada H, Entcheva-Dimitrov P, Ernst A, Rafeq S, Keating JH, Seward KP, Yarmus L. Respirology. 2018 Apr;23(4):399-405. doi: 10.1111/resp.13214.